Endo Gigantism Standard Approaches

---
name: endo-gigantism-standard-approaches
description: Recommends applying standard acromegaly treatment approaches to normalize GH and IGF-1 in patients with pituitary gigantism. Use when evaluating a child or adolescent with excessive linear growth prior to epiphyseal closure, elevated IGF-1, and nonsuppressed GH after glucose load.
---

# Apply standard approaches to normalize GH and IGF-1 in gigantism

## STEP 1 — Gather Information
Collect clinical history (growth velocity, pubertal stage), physical exam (acral enlargement, facial changes), labs (age‑adjusted serum IGF‑1, GH suppression after 75 g oral glucose tolerance test), and pituitary MRI with contrast to assess tumor size, cavernous sinus invasion, and chiasmal proximity.

## STEP 2 — Rule In / Rule Out
If IGF‑1 exceeds the age‑adjusted upper limit and GH fails to suppress to <0.4 µg/L after OGTT, with MRI confirming a GH‑secreting adenoma → rule in gigantism; otherwise rule out and consider alternative causes of overgrowth (e.g., genetic syndromes, precocious puberty).

## STEP 3 — Classify or Stratify
Stratify by surgical resectability: tumor confined to sella with minimal cavernous sinus invasion → primary transsphenoidal surgery; extensive cavernous sinus invasion or chiasmal compression making gross total resection unlikely → primary medical therapy.

## STEP 4 — Decide
For resectable tumors, perform transsphenoidal surgery; for unresectable disease or as adjuvant post‑surgery, initiate medical therapy (first‑line somatostatin receptor ligand, add pegvisomant if inadequate, consider dopamine agonist for mild IGF‑1 elevation) targeting age‑adjusted IGF‑1 normalization and random GH <1 µg/L.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on random GH alone for diagnosis; avoid long‑acting SRLs or pegvisomant in pregnancy without specialist input; do not delay surgery in rapidly progressive cases due to irreversible skeletal overgrowth; use age‑adjusted IGF‑1 norms; avoid radiotherapy as first‑line in children because of neurocognitive risk.

## Concrete Clinical Example
A 14‑year‑old presents with 10 cm/year growth, coarse facial features, and enlarged hands. IGF‑1 is 2× the upper limit for age, GH 2 µg/L after OGTT. MRI shows a 12 mm pituitary macroadenoma touching the cavernous sinus. Transsphenoidal surgery reduces tumor size but IGF‑1 remains elevated; monthly lanreotide 120 mg normalizes IGF‑1 at 6 months.

**Source:** Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700